Reviewer’s report

Title: A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma

Version: 2 Date: 6 October 2006

Reviewer: Daphne Bell

Reviewer’s report:

General
The authors have responded satisfactorily to comments within the previous review

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

Discretionary Revisions (which the author can choose to ignore)

What next?: Accept without revision

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:

I am an inventor on a patent describing EGFR mutations. I receive royalties resulting from the licensing of a genetic test for EGFR mutations.